Hypofractionated stereotactic radiotherapy for brain metastases

被引:19
|
作者
Schlienger, M. [1 ]
Nataf, F. [2 ]
Huguet, F. [1 ]
Pene, F. [1 ]
Foulquier, J. -N. [1 ]
Orthuon, A. [1 ]
Roux, F. -X. [2 ]
Touboul, E. [1 ]
机构
[1] Hop Tenon, AP HP, Serv Oncol Radiotherapie, F-75020 Paris, France
[2] Hop St Anne, Serv Neurochirurg, F-75014 Paris, France
来源
CANCER RADIOTHERAPIE | 2010年 / 14卷 / 02期
关键词
Brain metastases; Stereotactic radiotherapy; Hypofractionnated; Or radiosurgery; NONINVASIVE FIXATION; RADIATION-THERAPY; RADIOSURGERY; SINGLE; TUMORS; DEFINITION;
D O I
10.1016/j.canrad.2009.10.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - A survey of the literature has been performed to find arguments in order to help the choice between radiosurgery and hypofractionnated stereotactic radiotherapy in the treatment of brain metastases. Patients and methods. - A comparison of two groups of brain metastases treated with hypofractionnated stereotactic radiotherapy or radiosurgery, with or without WBRT was performed. Hypofractionnated stereotactic radiotherapy: there were eight series including 448 patients published from 2000 to 2009; treated with 5-6 MV X-Rays, non invasive head immobilization, a margin 2 to 10 mm; 24 to 40 Gy in three to five fractions; a 5 to 8 days duration in six series and 15-16 days in two other series. WBRT (30%); radiosurgery: there were 12 series (1994 to 2005) including 2157 patients; an invasive head immobilization, no margin; doses from 10 to 25 Gy; six series over 12 had Gamma Knife radiosurgery and six had Linacs X-Rays. WBRT (30 Gy/10 F/12 days) associated to radiosurgery in several series. The following parameters were compared: median GTV, median survival, 1-year survival rate, local control rate, necrosis and WBRT rates. Results. - Hypofractionnated stereotactic radiotherapy series: the parameters were respectively: 0,52-4,47 cm(3) (median 2,8 cm(3)); 5-16 months (median 8,7 months); 68,2-93% (median 82,5%); necrosis rate 3,1%; associated WBRT 30%. Radiosurgery series: the parameters were respectively: 1,3 to 5,5 cm(3) (median 2 cm(3)); 5,5 to 22 months (median 11 months); 71 to 95% (median 85%); 0,5 to 6% (median 2,4%); associated WBRT 58%. Results seem similar in the two groups: Hypofractionnated stereotactic radiotherapy with non invasive immobilization could theoretically treat all brain metastases sizes except lesions < 10 mm (500 mm(3)). In large volumes, > 4200 mm(3) GTV, the toxicity of hypofractionnated stereotactic radiotherapy was not reported, thus it was difficult to compare its results with the published reports of radiosurgery toxicity. WBRT was a confusing parameter. Obviously, this initial survey has important limitations, specifically its methodology. Conclusion. - Radiosurgery and hypofractionnated stereotactic radiotherapy could be used to treat brain metastases with GTV > 500 mm(3) and <= 4200 mm(3) (circle divide 20 mm); for GTV < 500 mm(3) (circle divide 10 mm) an invasive procedure with radiosurgery is necessary. For GTV > 4200 mm(3) (circle divide 20 mm), hypofractionnated stereotactic radiotherapy could be proposed, provided further studies, using 4 to 6 Gy fractions, a duration less or equal to 10-12 days and a margin of 2 mm will be performed. (c) 2009 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 50 条
  • [31] Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intract and resected brain metastases
    Nguyen, Timothy K.
    Sahgal, Arjun
    Detsky, Jay
    Atenafu, Eshetu G.
    Myrehaug, Sten
    Tseng, Chia-Lin
    Husain, Zain
    Heyn, Chris
    Maralani, Pejman
    Ruschin, Mark
    Perry, James
    Soliman, Hany
    [J]. NEURO-ONCOLOGY, 2020, 22 (01) : 84 - 93
  • [32] Treatment of Single or Multiple Brain Metastases by Hypofractionated Stereotactic Radiotherapy Using Helical Tomotherapy
    Nagai, Aiko
    Shibamoto, Yuta
    Yoshida, Masanori
    Wakamatsu, Koichi
    Kikuchi, Yuzo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (04) : 6910 - 6924
  • [33] Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
    Christine Kornhuber
    Stephan Ensminger
    Patrick Hübsch
    Martin Janich
    Chris Andre Leucht
    Dirk Vordermark
    Christian T. Dietzel
    [J]. Radiation Oncology, 18
  • [34] PREDICTORS OF LEPTOMENINGEAL DISEASE AFTER HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY FOR INTACT AND RESECTED BRAIN METASTASES
    Tim Nguyen
    Sahgal, Arjun
    Detsky, Jay
    Atenafu, Eshetu
    Myrehaug, Sten
    Tseng, Chia-Lin
    Husain, Zain
    Ruschin, Mark
    Heyn, Chris
    Soliman, Hany
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S96 - S96
  • [35] Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases
    Gallo, J.
    Garimall, S.
    Shanker, M.
    Castelli, J.
    Watkins, T.
    Olson, S.
    Huo, M.
    Foote, M. C.
    Pinkham, M. B.
    [J]. CLINICAL ONCOLOGY, 2022, 34 (03) : 179 - 186
  • [36] Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases
    Narayana, Ashwatha
    Chang, Jenghwa
    Yenice, Kamil
    Chan, Kelvin
    Lymberis, Stella
    Brennan, Cameron
    Gutin, Philip H.
    [J]. STEREOTACTIC AND FUNCTIONAL NEUROSURGERY, 2007, 85 (2-3) : 82 - 87
  • [37] Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions
    Lecomte, D. Dumont
    Lequesne, J.
    Geffrelot, J.
    Lesueur, P.
    Barraux, V
    Loiseau, C.
    Lacroix, J.
    Leconte, A.
    Emery, E.
    Thariat, J.
    Stefan, D.
    [J]. CANCER RADIOTHERAPIE, 2019, 23 (08): : 860 - 866
  • [38] A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases
    Bi, Nan
    Ma, Yuchao
    Xiao, Jianping
    Zhang, Hongmei
    Xu, Yingjie
    Tian, Yuan
    Li, Junling
    Zhang, Ye
    Liu, Qingfeng
    Wang, Kai
    Deng, Lei
    Wang, Wenqing
    Chen, Xuesong
    Liu, Feng
    Zhao, Ruizhi
    Yang, Siran
    Huang, Xiaodong
    Yi, Junlin
    Hu, Chen
    Li, Yexiong
    [J]. ONCOLOGIST, 2019, 24 (09): : E914 - E920
  • [39] Rates Of Radionecrosis In Re-Irradiation Of Brain Metastases Using Hypofractionated Stereotactic Radiotherapy
    Lee, M.
    Tseng, C. L.
    Detsky, J.
    Husain, Z. A.
    Ruschin, M. E.
    Lee, Y.
    Myrehaug, S. D.
    Sahgal, A.
    Soliman, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E720 - E720
  • [40] Treatment of brain metastases of renal cell cancer with combined hypofractionated stereotactic radiotherapy and whole brain radiotherapy with hippocampal sparing
    Vrana, David
    Studentova, Hana
    Matzenauer, Marcel
    Vlachova, Zuzana
    Cwiertka, Karel
    Gremlica, David
    Kalita, Ondrej
    [J]. ONCOLOGY LETTERS, 2016, 11 (06) : 3777 - 3781